GNPX Genprex, Inc. Stock Quote

GNPX [NASD]

Index	-	P/E	-	EPS (ttm)	-0.43	Insider Own	10.55%	Shs Outstand	47.61M	Perf Week	-3.07%
Market Cap	70.74M	Forward P/E	-	EPS next Y	-0.50	Insider Trans	0.00%	Shs Float	45.14M	Perf Month	-28.51%
Income	-19.10M	PEG	-	EPS next Q	-0.12	Inst Own	12.10%	Short Float	5.08%	Perf Quarter	-48.20%
Sales	-	P/S	-	EPS this Y	24.00%	Inst Trans	-0.55%	Short Ratio	5.80	Perf Half Y	-57.75%
Book/sh	0.95	P/B	1.66	EPS next Y	-11.10%	ROA	-43.10%	Target Price	8.00	Perf Year	-48.20%
Cash/sh	0.94	P/C	1.68	EPS next 5Y	-	ROE	-44.00%	52W Range	1.48 - 7.72	Perf YTD	-61.93%
Dividend	-	P/FCF	-	EPS past 5Y	-50.20%	ROI	-	52W High	-79.53%	Beta	-0.90
Dividend %	-	Quick Ratio	36.80	Sales past 5Y	-	Gross Margin	-	52W Low	6.76%	ATR	0.16
Employees	12	Current Ratio	39.30	Sales Q/Q	-	Oper. Margin	-	RSI (14)	29.71	Volatility	10.21% 8.29%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-1.60%	Profit Margin	-	Rel Volume	0.46	Prev Close	1.65
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	395.12K	Price	1.58
Recom	2.00	SMA20	-22.54%	SMA50	-32.65%	SMA200	-54.15%	Volume	179,989	Change	-4.24%

Jan-26-21

Initiated

National Securities

Buy

Apr-29-19

Initiated

Noble Capital Markets

Outperform

Nov-16-21 08:30AM	Genprex to Present in November CEO Roadshow Webinar Business Wire
Sep-30-21 05:21AM	JinkoSolar Provides Updates on Jinko Solar Co., Ltd.'s Proposed IPO in China PR Newswire
Sep-28-21 09:43PM	JinkoSolar Awarded "Top Brand PV USA 2021" by EUPD Research PR Newswire
01:53PM	Genprex Inc. Strengthens Management Team with Strategic Appointments Benzinga
06:50AM	Genprex Strengthens Management Team with Appointments of Industry Leaders Mark S. Berger, M.D. as Chief Medical Officer and Hemant Kumar, Ph.D. as Chief Manufacturing and Technology Officer Business Wire
Sep-27-21 06:49AM	JinkoSolar's New 7GW Ingot/Wafer Facility in Vietnam to Strengthen the Sustainability of its Global Supply Chain by 2022 PR Newswire
Sep-24-21 06:37AM	JinkoSolar's Subsidiary Jinko Solar Co., Ltd. Provides Preliminary Estimates of Revenue and Net Income for the First Nine Months of 2021 PR Newswire
Sep-20-21 07:00AM	Genprex to Participate in September Investor Conferences Business Wire
Jul-20-21 08:30AM	Genprex to Participate in a Monthly CEO Roadshow Webinar Series Business Wire
Jun-23-21 08:30AM	Genprex Announces Initiation of its Phase 1/2 Acclaim-1 Clinical Trial for REQORSA Immunogene Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung Cancer Following FDA Review Business Wire +12.73%
Jun-22-21 07:08PM	Is Genprex, Inc. (GNPX) A Good Stock To Buy Now? Insider Monkey
Jun-11-21 03:32AM	Companies Like Genprex (NASDAQ:GNPX) Are In A Position To Invest In Growth Simply Wall St.
May-19-21 08:30AM	Genprex Announces Participation in Noble Capital Markets Virtual Roadshow Series Business Wire
May-10-21 08:30AM	Genprex to Participate in Upcoming May Investor Conferences Business Wire
May-06-21 09:05AM	Genprex In-Licenses Additional Gene Therapy Technologies for Treatment of Lung Cancer Business Wire -5.79%
09:00AM	Diamond Equity Research Emerging Growth Invitational Spring 2021 Virtual Conference ACCESSWIRE
May-05-21 08:55AM	Genprex Announces Centralized Institutional Review Board Approval for Acclaim-1 Clinical Trial in Non-Small Cell Lung Cancer Business Wire
May-04-21 09:32AM	Genprex Initiates Site Recruitment for Acclaim-2 Clinical Trial for the Treatment of Non-Small Cell Lung Cancer Business Wire
Apr-21-21 08:30AM	Genprex to Participate in CEO Roadshow Webinar Series Business Wire +13.53%
Apr-20-21 08:30AM	Genprex to Receive Inaugural "License of the Year" Award from University of Pittsburgh Innovation Institute in Recognition of Advances Made with Gene Therapy Program in Diabetes Business Wire -10.99%
Apr-12-21 08:30AM	Genprex Collaborators Report Positive Preclinical Data for REQORSA Immunogene Therapy in Non-Small Cell Lung Cancer at the 2021 AACR Annual Meeting Business Wire -5.16%
Apr-05-21 08:30AM	Genprex to Present at the 2021 Virtual Cell & Gene Meeting on the Mediterranean Business Wire
Mar-30-21 08:30AM	Genprex Announces Preclinical Data for TUSC2 Immunogene Therapy in Non-Small Cell Lung Cancer to Be Featured in Two Presentations at the 2021 American Association for Cancer Research Annual Meeting Business Wire
Mar-24-21 08:30AM	Genprex to Present at the Spring 2021 Oncology Investor Conference on March 29 Business Wire -5.15%
Mar-01-21 08:30AM	Genprex to Participate in Upcoming March Investor Conferences Business Wire
Feb-09-21 08:30AM	Genprex, Inc. Announces $25 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules, Without Warrants Business Wire -13.43%
07:27AM	Inspect the Fingerprints on the Genprex Offering, Before Making a Move TheStreet.com
Feb-08-21 03:30PM	Genprex Announces Formation of Clinical Advisory Board Business Wire +22.72%
08:35AM	Small and Microcap Company Investor Presentations Now Available for On-Demand Viewing PR Newswire
Feb-04-21 08:30AM	Genprex Recognizes World Cancer Day Business Wire +9.95%
Feb-01-21 01:30PM	Genprex Issues Shareholder Letter and Provides Corporate Update Business Wire +8.28%
Jan-28-21 08:35AM	Live Investor Conference & Webinar: Small and Microcap Company Showcase on February 4th PR Newswire
Jan-27-21 08:30AM	Genprex to Present at the Virtual Investor Conference Small and Microcap Showcase on February 4 Business Wire -6.78%
Jan-21-21 08:30AM	Genprex to Present its Cutting-Edge Gene Therapies at the MoneyShow Accredited Investors Virtual Expo Business Wire
Jan-14-21 08:30AM	Genprex to Present at NobleCon17 on January 19 Business Wire
Jan-13-21 09:00AM	Genprex Achieves Major Manufacturing Milestone for REQORSA Immunogene Therapy for Upcoming Trials to Treat Non-Small Cell Lung Cancer Business Wire
Dec-24-20 01:02PM	Genprex, Inc. Announces Closing Of $12 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules Without Warrants Business Wire -14.88%
Dec-23-20 12:40PM	Let's Look at the Big Picture of Genprex TheStreet.com +23.27%
Dec-22-20 01:15PM	Genprex, Inc. Announces $12 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules, Without Warrants Business Wire +12.31%
12:10PM	Genprex's Leading Drug Candidate Is Currently Being Developed As A Treatment For Lung Cancer Benzinga
09:32AM	Genprex Completes Manufacturing Scale-Up for Clinical-Grade Production of REQORSA Immunogene Therapy for Upcoming Acclaim-1 and Acclaim-2 Clinical Trials For Lung Cancer Business Wire
Dec-17-20 08:47AM	Genprex (GNPX) Looks Good: Stock Adds 6.5% in Session Zacks
Dec-08-20 08:16AM	Genprex Completes Manufacturing Technology Transfer for Novel Gene Therapy Business Wire
Dec-03-20 08:17AM	Genprex to Present at the Benzinga Global Small Cap Conference on December 8 Business Wire
Nov-30-20 02:05PM	Genprex Initiates Site Recruitment for Acclaim-1 Clinical Trial for the Treatment of Non-Small Cell Lung Cancer Business Wire
Nov-24-20 09:30AM	Diamond Equity Research 2020 Virtual Emerging Growth Invitational ACCESSWIRE
08:16AM	Genprex to Participate at the Diamond Equity Research Emerging Growth Invitational on December 1 Business Wire
Nov-11-20 08:16AM	Genprex to Participate in Panel at Life Sciences Summit on November 17 Business Wire
Nov-10-20 08:17AM	Genprex Strengthens Scientific Advisory Board with Appointment of Lead Researcher of University of Pittsburgh, George K. Gittes, MD Business Wire
Oct-30-20 08:17AM	Genprex Unveils New Branding for Upcoming Combination Clinical Trials in Non-Small Cell Lung Cancer Business Wire -7.93%
Oct-29-20 08:16AM	Genprex Receives Conditional FDA Acceptance of Proprietary Name REQORSA for Lead Drug Candidate for Treatment of Non-Small Cell Lung Cancer Business Wire +14.24%
Oct-26-20 08:16AM	Genprex Promotes Eric Chapdelaine to Vice President of Manufacturing Business Wire
Oct-07-20 08:17AM	Genprex to Present at Zooming with LD Micro on October 14, 2020 Business Wire +5.40%
Oct-06-20 08:16AM	Genprex to Present at the Alliance for Regenerative Medicines Virtual Cell and Gene Meeting on the Mesa Business Wire
Sep-21-20 08:17AM	Genprex Names Seasoned IP Executive, Thomas C. Gallagher, as Senior Vice President of Intellectual Property and Licensing Business Wire -5.00%
Sep-09-20 04:25PM	This Biotech Appears to Have the Right Formula for Investors TheStreet.com
Sep-02-20 05:36PM	LD Micro 360 Companies Set to Present this Week. ACCESSWIRE
08:17AM	Genprex Appoints William E. Gannon, Jr., MD, MBA, as Vice President of Regulatory Affairs Business Wire
Aug-26-20 08:17AM	Genprex to Present at The LD 500 Virtual Conference Business Wire -6.31%
08:17AM	Genprex to Present at The LD 500 Virtual Conference ACCESSWIRE
Aug-05-20 03:34PM	LD Micro-Announces Preliminary List of Presenters for the LD 500. ACCESSWIRE
Jul-31-20 08:17AM	Genprex to Present at Proactives One2One Virtual Investor Forum on August 4, 2020 Business Wire
Jul-30-20 08:16AM	Genprex CEO Participates in a Second-Round Live Interview on the "Big Biz Show" Business Wire
Jul-21-20 12:58PM	Sometimes, Stories Do Come True TheStreet.com +10.00%
08:17AM	National Institutes of Health (NIH) Awards Research Grant of $2.59 Million to University of Pittsburgh for Diabetes Gene Therapy Technology Licensed by Genprex Business Wire
Jun-29-20 08:16AM	Genprex Added to Russell 3000® Index Business Wire
Jun-25-20 08:17AM	Genprex Receives USAN Approval of Non-Proprietary Name for Lead Drug Candidate Business Wire
Jun-24-20 08:16AM	Genprex CEO to Interview Live on "The Big Biz Show" Business Wire +17.42%
Jun-16-20 08:17AM	Genprex Expands Manufacturing Program with Aldevron to Advance Oncoprex Clinical Development Business Wire
Jun-09-20 08:17AM	Genprex Scheduled to Join Russell 3000® Index Business Wire +9.80%
Jun-08-20 08:17AM	Genprex to Present at the MoneyShow June Virtual Event Business Wire
May-28-20 08:17AM	Genprex Announces Receipt of $2.5 Million in Cash from Recent Warrant Exercises Business Wire
May-05-20 01:00PM	Genprex Is Soaring - And There's a One Word Reason Why TheStreet.com +51.52%
08:17AM	Genprex Enters Into Exclusive Worldwide Patent and Technology License Agreement for Combination of its TUSC2 Gene Therapy with Immunotherapies Business Wire
May-04-20 08:17AM	Genprex Issues April 2020 Shareholder Letter Business Wire
Apr-21-20 08:17AM	Genprex Appoints Shannon Inman as Vice President of Global Clinical Operations Business Wire
Mar-24-20 08:17AM	Genprex Bolsters Board of Directors, Appoints Three Biotechnology and Healthcare Industry Leaders Business Wire +27.31%
Mar-23-20 08:17AM	Genprex Strengthens Leadership Team with the Appointment of Two Accomplished Life Science Executives Business Wire -9.56%
Mar-05-20 08:05AM	Lead Researcher Behind Genprexs Diabetes Gene Therapy Featured in New Video Interview Business Wire -7.30%
Mar-04-20 08:00AM	Genprex to Present at the 2020 LD Micro Virtual Conference ACCESSWIRE
Mar-03-20 08:17AM	Genprex to Present at the 2020 LD Micro Virtual Conference Business Wire -7.13%
Feb-21-20 04:15PM	Genprex, Inc. Announces Closing of $17,500,000 Common Stock Offering At-The-Market and Without Warrants Business Wire +21.69%
Feb-20-20 10:22AM	Those Golden Rule TheStreet.com +12.31%
Feb-19-20 09:23AM	Genprex, Inc. Prices $17,500,000 Common Stock Offering Priced At-The-Market and Without Warrants Business Wire -20.41%
08:05AM	Benzinga Pro's Top 5 Stocks To Watch For Wed., Feb. 19, 2020: BLPH, GRPN, VIVE, CODX, GNPX Benzinga
Feb-11-20 08:17AM	Genprex and University of Pittsburgh Sign Exclusive License Agreement for Potentially Curative Gene Therapy Candidate for Diabetes Business Wire +29.84%
Feb-06-20 08:17AM	Genprex Regains Compliance with Nasdaq Minimum Bid Price Requirement Business Wire -6.99%
Feb-05-20 09:00AM	Genprex to Focus Its Clinical Efforts on Oncoprex in Combination Therapy with Osimertinib for Non-Small Cell Lung Cancer (NSCLC) Business Wire
Feb-03-20 08:17AM	Genprex to Present at NobleCon16 Investor Conference Business Wire -7.18%
Jan-29-20 08:18AM	Independent Researchers Find Genprexs TUSC2 May Be a Novel Target and Biomarker for Thyroid Cancer Therapy Business Wire +23.44%
Jan-28-20 08:00AM	Genprex, Inc. Announces Closing of $8 Million At-The-Market Common Stock Offering Business Wire
Jan-24-20 07:00AM	Genprex: The Bad and the Good of Capital Raises TheStreet.com -8.57%
Jan-23-20 09:00AM	Genprex, Inc. Prices $8,000,000 Common Stock Offering Priced At-The-Market Business Wire -25.93%
Jan-22-20 10:54AM	Genprex's stock rallies on FDA fast-track designation MarketWatch +64.35%
Jan-21-20 08:00AM	Genprex Receives U.S. FDA Fast Track Designation for Gene Therapy that Targets Lung Cancer Business Wire +219.44%
Jan-06-20 08:00AM	Genprex to Present at Biotech Showcase 2020 in San Francisco Business Wire +7.44%
Nov-20-19 11:15AM	Genprex Announces $1.26 Million Registered Direct Offering Business Wire -43.55%
Nov-19-19 08:00AM	Genprex Reports Positive Preclinical Data for the Treatment of Some of the Most Resistant Metastatic Lung Cancers Business Wire +60.29%
Nov-04-19 08:00AM	Genprex Issues Lung Cancer Prevention Measures in Support of Lung Cancer Awareness Month Business Wire
Oct-15-19 08:00AM	MicroCap Rodeo Investor Conference Lineup for October 15 and 16, 2019 ACCESSWIRE

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes who currently have limited treatment options. The company works with institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Its lead product candidate is REQORSA (GPX-001), which is in preclinical stage for the treatment of non-small cell lung cancer (NSCLC). It is also developing GPX-002, a preclinical stage gene therapy for diabetes. The company also offers ONCOPREX, a nanoparticle delivery system. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
LONGNECKER BRENT M	Director	Apr 05	Buy	4.15	15,000	62,250	15,000	Apr 07 04:41 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience